Metabolic interaction of recombinant interferon-β and zidovudine in AIDS patients

M. Nokta, J. P. Loh, S. M. Douidar, A. E. Ahmed, Richard B Pollard

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Zidovudine (AZT), the only currently approved drug for treatment of human immunodeficiency virus (HIV) in AIDS, is known to be metabolized by mammalian systems to a variety of metabolites including 3'-azido-3'-deoxy-5'-O- glucuronide (GAZT). Interferons (IFNs) are known to alter the microsomal enzyme system responsible for the metabolism of some compounds. The aim of the present study was to investigate the effect of combination therapy of recombinant (r) IFN-β and AZT on the rates of metabolism of AZT in AIDS patients. AZT was given orally (200 mg every 4 h) for 8 weeks prior to initiation of rIFN-β therapy (45 x 106 U/day, s.c.). Serum samples from 8 patients were obtained prior to and at days 3 and 15 following initiation of rIFN-β therapy. Serum was analyzed by high-performance liquid chromatography (HPLC) for both AZT and GAZT. The serum data were analyzed by a computer- assisted pharmacokinetics program that calculates rates of AZT metabolism. The half life for AZT was increased approximately two-fold by day 15. The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-β therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively. The volume of distribution of AZT was 2 l/kg at day 0 and increased to 3.2 and 3.5 l/kg on days 3 and 15, respectively. In conclusion, the results indicate that rIFN-β inhibits the rate of AZT metabolism in AIDS patients.

Original languageEnglish (US)
Pages (from-to)159-164
Number of pages6
JournalJournal of Interferon Research
Volume11
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Zidovudine
Interferons
Acquired Immunodeficiency Syndrome
Serum
Therapeutics
Glucuronides
Half-Life
Pharmacokinetics
High Pressure Liquid Chromatography
HIV
Enzymes
Pharmaceutical Preparations
3'-azido-3'-deoxy-5'-O-beta-glucopyranuronosylthymidine

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Metabolic interaction of recombinant interferon-β and zidovudine in AIDS patients. / Nokta, M.; Loh, J. P.; Douidar, S. M.; Ahmed, A. E.; Pollard, Richard B.

In: Journal of Interferon Research, Vol. 11, No. 3, 1991, p. 159-164.

Research output: Contribution to journalArticle

Nokta, M. ; Loh, J. P. ; Douidar, S. M. ; Ahmed, A. E. ; Pollard, Richard B. / Metabolic interaction of recombinant interferon-β and zidovudine in AIDS patients. In: Journal of Interferon Research. 1991 ; Vol. 11, No. 3. pp. 159-164.
@article{2a3da8559d8a4964b9ebb0236001cf10,
title = "Metabolic interaction of recombinant interferon-β and zidovudine in AIDS patients",
abstract = "Zidovudine (AZT), the only currently approved drug for treatment of human immunodeficiency virus (HIV) in AIDS, is known to be metabolized by mammalian systems to a variety of metabolites including 3'-azido-3'-deoxy-5'-O- glucuronide (GAZT). Interferons (IFNs) are known to alter the microsomal enzyme system responsible for the metabolism of some compounds. The aim of the present study was to investigate the effect of combination therapy of recombinant (r) IFN-β and AZT on the rates of metabolism of AZT in AIDS patients. AZT was given orally (200 mg every 4 h) for 8 weeks prior to initiation of rIFN-β therapy (45 x 106 U/day, s.c.). Serum samples from 8 patients were obtained prior to and at days 3 and 15 following initiation of rIFN-β therapy. Serum was analyzed by high-performance liquid chromatography (HPLC) for both AZT and GAZT. The serum data were analyzed by a computer- assisted pharmacokinetics program that calculates rates of AZT metabolism. The half life for AZT was increased approximately two-fold by day 15. The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-β therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively. The volume of distribution of AZT was 2 l/kg at day 0 and increased to 3.2 and 3.5 l/kg on days 3 and 15, respectively. In conclusion, the results indicate that rIFN-β inhibits the rate of AZT metabolism in AIDS patients.",
author = "M. Nokta and Loh, {J. P.} and Douidar, {S. M.} and Ahmed, {A. E.} and Pollard, {Richard B}",
year = "1991",
language = "English (US)",
volume = "11",
pages = "159--164",
journal = "Journal of Interferon Research",
issn = "0197-8357",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Metabolic interaction of recombinant interferon-β and zidovudine in AIDS patients

AU - Nokta, M.

AU - Loh, J. P.

AU - Douidar, S. M.

AU - Ahmed, A. E.

AU - Pollard, Richard B

PY - 1991

Y1 - 1991

N2 - Zidovudine (AZT), the only currently approved drug for treatment of human immunodeficiency virus (HIV) in AIDS, is known to be metabolized by mammalian systems to a variety of metabolites including 3'-azido-3'-deoxy-5'-O- glucuronide (GAZT). Interferons (IFNs) are known to alter the microsomal enzyme system responsible for the metabolism of some compounds. The aim of the present study was to investigate the effect of combination therapy of recombinant (r) IFN-β and AZT on the rates of metabolism of AZT in AIDS patients. AZT was given orally (200 mg every 4 h) for 8 weeks prior to initiation of rIFN-β therapy (45 x 106 U/day, s.c.). Serum samples from 8 patients were obtained prior to and at days 3 and 15 following initiation of rIFN-β therapy. Serum was analyzed by high-performance liquid chromatography (HPLC) for both AZT and GAZT. The serum data were analyzed by a computer- assisted pharmacokinetics program that calculates rates of AZT metabolism. The half life for AZT was increased approximately two-fold by day 15. The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-β therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively. The volume of distribution of AZT was 2 l/kg at day 0 and increased to 3.2 and 3.5 l/kg on days 3 and 15, respectively. In conclusion, the results indicate that rIFN-β inhibits the rate of AZT metabolism in AIDS patients.

AB - Zidovudine (AZT), the only currently approved drug for treatment of human immunodeficiency virus (HIV) in AIDS, is known to be metabolized by mammalian systems to a variety of metabolites including 3'-azido-3'-deoxy-5'-O- glucuronide (GAZT). Interferons (IFNs) are known to alter the microsomal enzyme system responsible for the metabolism of some compounds. The aim of the present study was to investigate the effect of combination therapy of recombinant (r) IFN-β and AZT on the rates of metabolism of AZT in AIDS patients. AZT was given orally (200 mg every 4 h) for 8 weeks prior to initiation of rIFN-β therapy (45 x 106 U/day, s.c.). Serum samples from 8 patients were obtained prior to and at days 3 and 15 following initiation of rIFN-β therapy. Serum was analyzed by high-performance liquid chromatography (HPLC) for both AZT and GAZT. The serum data were analyzed by a computer- assisted pharmacokinetics program that calculates rates of AZT metabolism. The half life for AZT was increased approximately two-fold by day 15. The rate of metabolism of AZT was diminished from 1.43 h-1 prior to IFN-β therapy, to 0.4 h-1 and 0.05 h-1 at days 3 and 15, respectively. The volume of distribution of AZT was 2 l/kg at day 0 and increased to 3.2 and 3.5 l/kg on days 3 and 15, respectively. In conclusion, the results indicate that rIFN-β inhibits the rate of AZT metabolism in AIDS patients.

UR - http://www.scopus.com/inward/record.url?scp=0026366198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026366198&partnerID=8YFLogxK

M3 - Article

C2 - 1919075

AN - SCOPUS:0026366198

VL - 11

SP - 159

EP - 164

JO - Journal of Interferon Research

JF - Journal of Interferon Research

SN - 0197-8357

IS - 3

ER -